Apellis oral complement inhibitor

Apellis Pharmaceuticals is developing an oral small-molecule inhibitor of the complement pathway. Currently in the preclinical stage, this asset is part of Apellis's strategy to expand its complement-targeting portfolio beyond its lead peptide-based C3 inhibitors, such as pegcetacoplan. While the specific molecular target within the complement cascade (e.g., C3, Factor D, or Factor B) has not been publicly disclosed, the program is designed to provide an oral administration option for complement-mediated diseases, potentially offering improved patient convenience and expanded therapeutic applications compared to injectable modalities.

Other names

Oral complement inhibitor